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Introduction/DNP Capstone Overview
Prescription drug abuse has become an epidemic problem in many states, including Kentucky.
In 2012, the state of Kentucky sought to decrease the number of deaths in the state related to
overdoses of prescription medications. As a result, urine drug screening was mandated by the
Kentucky Board of Medical Licensure and recommended by the Kentucky Board of Nursing to
assess and monitor for appropriate use of prescription medications (http://odcp.ky.gov). These
requirements were implemented as a portion of House Bill 1: The Pill Mill Bill. Although House
Bill 1 was originally intended to address medications for the treatment of pain, each professional
board adapted the law to include many of the drugs of abuse for Kentucky. House Bill 1 has been
successful in decreasing the number of prescriptions of pain and anxiolytic medications; for
example, the Office of Drug Control Policy reports that since the enactment of this legislation,
prescriptions of medications containing hydrocodone and oxycodone have decreased by 11.8%,
oxymorphone has decreased by 44.5%, and alprazolam has decreased by 14.5%
(http://odcp.ky.gov/, 2013).
The prescribing practices of nurse practitioners who prescribe controlled substances can be
informed and guided by Urine Drug Screening (Gourlay, Heit, & Caplan, 2012). A variety of
methods and screening sensitivity is available and not all of those are appropriate in all practice
sites. Each provider should review their practice type and choose the method of urine testing that
allow them to best monitor those prescribed medications (Hammett-Staber, Pesce, & Cannon,
2002; Perrone, De Roos, Jayaraman, & Hollander, 2001).
Knowledge and comfort levels related to urine drug screening and interpretation have been
studied in family physicians and internal medicine resident (Reisfield, Webb, Bertholf, Sloan, &
Wilson, 2011). Those studies indicate that internal medicine residents and family physicians have
a knowledge gap related to urine drug screening. Interpretation of drug screening and accurate use
of those screens can be problematic (Pesce, West, City, & Strickland, 2012). Providers use urine
drug testing to assist and monitor potential drugs of abuse and often use those results to make
clinical decisions about medication management (Pesce et al., 2012). If the provider does not
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have a solid understanding of the results and interpretation, they can potentially err in prescribing
medications in inadequate or excessive dose ranges for illnesses such as chronic pain (Larson &
Richards, 2009). Providers are expected to manage patients who have substance abuse and
dependence, but may not have received adequate training in the assessment and management of
substance use disorders, including the use of urine drug screening (Rasyidi, Wilkins, &
Danovitch, 2012).
This DNP Capstone seeks to the review the literature surrounding provider knowledge of urine
drug testing, evaluate the use of psychiatric mental health nurse practitioners as treating
professionals, and to investigate the knowledge of current nurse practitioners related to urine drug
testing.
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Manuscript 1

Prescribing Provider Knowledge of Urine Drug Testing: What Do They Know?
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Introduction
In the last 20-30 years, the availability of prescription medications for the treatment of
chronic or acute pain, anxiety, attention deficit disorders, and problems with sleep has increased.
Along with this increase in prescription medications, researchers have seen the rates of misuse
increase (Trust for America’s Health, 2013). The Substance Abuse and Mental Health Services
Administration [SAMHSA] estimated in 2011 that there are over 6 million Americans abusing or
misusing prescription medications (SAMHSA, 2011).

Prescription drug abuse and misuse is a

costly problem in both primary and acute care. In emergency departments, the numbers of
unintentional overdoses, drug poisoning deaths, and children treated for poisoning has increased
since 1999 (Trust for America’s Health, 2013). The percentage of increase varies by resource.
Strategies to decrease prescription drug abuse have included health policy and law
changes, provider education, increased access to treatment and referral, and communication
among states to prevent doctor shopping (Gourlay, Heit, & Caplan, 2012; Hammett-Staber,
Pesce, & Cannon, 2002; Kentucky Cabinet for Health and Family Services, 2013). Provider
education after graduation can be variable and may range from 3-12 hours related to substance
abuse (Trust for America’s Health, 2013). Health policy and law may include prescription drug
monitoring programs, physical examination requirements of providers, requiring photo
identification to fill prescription medications, and “doctor shopping” statutes (SAMHSA, 2013).
Providers attempt to reduce prescription drug abuse with a variety of methods, such as pill
counting and random urine drug testing (Gourlay et al., 2012). The focus of this review will be to
evaluate the literature available on provider knowledge of urine drug testing and interpretation.
Background
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Urine drug testing is a critically important tool in the treatment of disease and the
assessment and management of prescription drug abuse (Nafziger & Bertino, 2009). Urine drug
testing, along with appropriate assessment and a review of drug use history can add valuable
information to the clinical picture. Random testing of adolescents in drug treatment programs
has been shown to improve program compliance (Vakili, Currie, & El-Guebaly, 2009).
Providers in chronic pain treatment programs utilize urine drug testing to investigate compliance
and possible abuse (Larson & Richards, 2009). Drug testing has also been indicated to deter
potential abuse of medications, as indicated in a 2002 review of the Department of the Navy
drug testing programs (Borack, 2002).
Two models of urine drug testing currently exist. The first model is considered a forensic
model, and was initiated through the criminal justice system. In the forensic model, the urine
drug testing is used to ensure compliance with prescribed medications. The compliance could be
mandated by the criminal justice system or by workplace settings (Pesce & West, 2011). The
second model of drug testing is considered a therapeutic model. In the therapeutic model, the
prescribing provider uses urine drug testing to guide decision making on optimal treatment,
based upon the levels of substances in the patient’s body. Using the therapeutic model, the
patient’s urine can be used to assess metabolites of many medication classes (Jaffee, Trucco,
Teter, Levy, & Weis, 2008). Those tests can then be used to assist with clinical decision making
as well as determining patient compliance with the prescription regimen.
Although skin, hair, nails, sweat, and saliva are used for laboratory drug testing, urine
remains the most common because of collection ease (Moeller, Lee, & Kissack, 2008). Urine
drug testing is becoming increasingly more complex with greater specificity and sensitivity.
Patients with addictions and polypharmacy frequently do not provide accurate or complete
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reports of all medications used during the frame of reference for the drug testing, resulting in a
need for the provider to use more sophisticated testing to determine drug status (Vaswani, 2003).
Urine drug testing can provide additional information that allows providers to screen for drugs of
abuse as well as other prescribed medications.
The specificity of urine drug testing depends on the type of testing used. One type of
testing is enzyme-immuno-assay testing (EIA), which uses antibodies to detect drugs in the
urines. This method is commonly used to detect opiates and benzodiazepines. Gas
chromatography and mass spectroscopy testing (GCMS) separates and isolates the specific drug
(i.e. morphine or diazepam) and gives the prescriber a quantity of the drug found. GCMS allows
the prescriber to have a repeatable, accurate, and objective measure to determine therapeutic and
illicit drug usage (Tenore, 2010). Gas chromatography has been considered the standard for
conformational analysis until recent years, when more laboratories began using liquid
chromatography (Rummell, 2012).
It is important to note that the assay processes within each laboratory performing the test
may differ and that qualitative results should be reviewed with each individual laboratory to
ensure that the prescribing provider is making appropriate decisions based on the results
(Melanson et al., 2010). The prescribing provider’s decisions can affect the patient drastically,
and the use of inaccurate laboratory values or inaccurate interpretation can cause negative
outcomes for the patient. Patient diseases or pain may be undertreated, there may be criminal
complaints, or patients may be falsely accused of diversion. Diversion in the clinical setting
refers to misuse of medications that can include sharing or selling medications.
Recommendations for treatment can also depend on verification of the patient’s drug use
(Patterson, 2008).
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False positive results can complicate the clinical picture and the prescribing clinician
should be aware of substances that can produce those false positive/negative results.
Occasionally, medications without abuse potential can provide a false-positive result. The most
common classes of medications that have false positive results are antihistamines, antipsychotics,
antidepressants, antibiotics, and analgesics (Braham, Yeager, Fox, Farmer, & Palmer, 2010). It
is important for the prescribing clinician to understand both the active drugs and their
metabolites (Dasgupta, 2009). It is also important to verify those false positive results with
additional testing methods. If the provider has used point-of-care testing to screen patients, those
positive results should then be quantified to determine which drugs created the positive results.
It is a common practice for patients to “beat” urine drug tests by altering results in some
way. Patients who are not observed giving the urine sample may have the ability to “swap” a
separate urine sample that would be free of illegal substances but would have the prescribed
substances. Dilution is an additional strategy to change the results of urine drug tests. In an
attempt to decrease the detectable substance, the patient ingests large quantities of liquids or adds
water to the urine sample (Mikkelsen & Ash, 1998). The last method used by patients to alter
urine drug test results is adulteration of the sample. Patients can add substances to the urine that
will inactivate results. Most often, household items are used in the adulteration process and may
include soaps, bleaches, acidic juices, and cleaning chemicals. The efficacy of those adulterants
varies based upon the strength and “freshness” of the urine sample (Hedayati, Tajic, & Kazemi,
2008).
Understanding and interpreting urine drug testing is a complex process and providers
using these tests should have a basic understanding of the strengths and limitations of each
screen.
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Methods
A literature review was conducted to describe the prescribing practices of providers who
practice in the US. In the United States, prescribing is limited to providers such as physicians,
podiatrists, veterinarians, and physician assistants, dentists, advanced practice nurses, nurse
anesthetists, and nurse midwives. In a very limited number of states, optometrists and
psychologists may prescribe as well. This review will focus on physicians, physician assistants
(PAs), and advanced practice nurses (APNs).
The volume of literature was very limited regarding the knowledge levels of advanced
practice nurses and physicians’ assistants, and the review was expanded to include some
information about the prescribing practices of those groups. There were no limits on the age of
the articles searched. Search terms included: physician assistants, nurse practitioners,
knowledge, interpretation, urine drug testing, urine drug screening, urine drug toxicology,
prescribing practices, and combinations of those listed above. Search engines included
CINAHL, Ebscohost, Cochrane, Medline, and NIH. The search included books and journals
from nursing, allied health, medicine, psychiatry, psychology, addictions, substance abuse, and
mental health. References lists from sources were included; clinical toxicologists were also
consulted for landmark studies related to provider interpretation and knowledge.
Physician Knowledge
There are few studies related to the prescribing providers' knowledge levels of urine drug
testing. Two studies reported similar results in interpretation response of physicians. In 2006,
Levy et al. evaluated urine drug testing in ambulatory medicine. Surveys were created, as no
tools were available to assess physician knowledge and practices. The survey was administered
to 359 physicians with a 42% response rate. The responses of the physicians indicated wide use
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of urine drug testing but poor collection methods and improper use of validation techniques. In
addition, only 10% of participants were able to answer all of the questions correctly.
Reisfield et al. (2007) created a seven question survey and administered it to 60
physicians to assess knowledge and proficiency in urine drug testing interpretation. None of the
physicians tested were able to answer all seven questions correctly and less than twenty percent
answered more than half of them correctly. The test scores of physicians who ordered urine drug
testing were generally better compared to those who did not order urine drug tests. The study
results indicated that those who order drug testing generally have a poor understanding of the
information provided by the test. It also indicated that in order to ensure appropriate responses
to testing, those physicians should work with chemists/toxicologists when ordering and
interpreting tests. Those studies imply an overall gap between providers ordering urine drug
screens and what they actually understand about the tests they are ordering.
A second survey from Levy et al. (2007) in the Journal of Adolescent Health, reported
that physicians had difficulty agreeing on indications for drug testing in general medical settings
and that most disagreed with testing in school settings. The study recommended professional
guidelines to assist with effective use of the procedure.
The most recent study of physician knowledge and interpretation of urine drug testing
involved 99 residents who responded to a 7 item survey. The survey included a question about
their confidence in interpretation of the results (Starrels, Fox, Kunins, & Cunningham, 2012).
Over half the residents indicated that they were confident in their abilities to interpret results, but
nearly three-fourths of the residents answered three or fewer questions correctly. The study also
adjusted for gender and reported that female residents’ confidence responses were positively
correlated with knowledge.
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None of the studies reviewed used the same questionnaire to determine provider
knowledge and interpretation of urine drug testing.

This limits the ability to compare the

provider responses or to analyze the inconsistencies in their responses. The questionnaires
cannot be used to compare knowledge on specific medications or specific knowledge deficits.
Advanced Practice Nurse and Physician Knowledge
The literature search indicated that there are no published studies, that evaluate APN and
PA knowledge of urine drug screen interpretation. Hooker and Cipher (2005) found that PAs
and APNs have exhibited similar prescribing practices. Another analysis of prescribing practices
indicated that PAs were slightly more likely than physicians to prescribe a controlled substance
in a primary care visit (Cipher, Hooker, & Guerra, 2006).
Care and outcomes of patients seen by PAs and APNs have been shown to be similar to
those of physicians (Institute of Medicine [IOM], 2011; (Kentucky Coalition of Nurse
Practitioner and Nurse Midwives [KCNPNM], 2010, 2011). With similar prescribing practices it
is reasonable to expect similar evidence based monitoring of prescribed medications using urine
drug testing (Moeller et al., 2008). If APNs are prescribing the same medications, they likely
have the same or similar knowledge deficits in urine drug testing and interpretation.
Conclusion
Despite the indication in the literature that urine drug testing can be a valid and viable
tool for managing patient drug status, there is an absence of literature to support prescribing
provider knowledge and understanding of urine drug screening. Physicians, APNs and PAs are
all prescribing medications that have the potential for abuse, but may have different perspectives
about the patient’s potential to abuse them (Hagemeier, Gray, & Pack, 2013). Monitoring
medications and interpretation of urine drug testing adds information to the clinical presentation

10

of the patient and can be used provide adequate management of many conditions (Moeller et al.,
2008). The studies related to physicians all indicate that there is a difference between what
physicians believe they know and what they actually understand about urine drug testing and
interpretation (Reisfield, Webb, Bertholf, Sloan, & Wilson, 2007; Starrels et al., 2012). If they
do not understand the tests they are ordering, it is possible that their clinical decision making in
influenced by those deficits, possibly resulting in negative outcomes for patients. PAs and APNs
are gaining the opportunity to prescribe and their practices are expanding (Morgan, De Oliveira,
& Short, 2011). If they are prescribing in the same patterns as physicians, it is reasonable to
expect similar confidence levels and misunderstandings about their knowledge related to urine
drug screening.
Implications for Practice
There have been many recent studies encouraging the use of PAs and APNs to help
improve access to primary care services across the United States (Deloitte, 2013; IOM, 2011; &
Morgan et al., 2011). As the scope and standards of APN practice expands, it is critically
important to understand the weaknesses and limitations to that practice. Addictions to both
prescription drugs and illegal substances are on the rise and prescribing providers need to
understand the methods to minimize that potential (SAMHSA, 2012). Initially, all prescribing
provider knowledge should be assessed with a standardized tool to determine the knowledge
deficits. Second, those deficits should be used to create continuing education programs to target
that deficit. Third, addiction and abuse screening should be a part of the educational preparation
of each prescribing provider type and needs to be addressed prior to graduation. Addiction and
substance abuse management can be improved if providers have good understanding of the tools
available for clinical monitoring and are using those tools appropriately.
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Psychiatric APRN's: Removing Barriers in Kentucky
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Abstract
Purpose: To support the expansion of Psychiatric Advanced Practice Registered Nurses
(APRN) care in the state of Kentucky by removing the limitations of the current Administrative
Regulation.
Data Sources: Kentucky Health Facts, Department of Health and Human Services,
Substance Abuse and Mental Health Services Administration, Centers for Medicare and
Medicaid Services, and related literature.
Conclusions: Mental health care is inaccessible in Kentucky and increasing patient
access to Psychiatric APRNs could improve access to mental health care for Kentucky Residents.
Kentucky has a critical shortage of Psychiatrists and limiting access to prescribing providers is
not in the best interest of Kentuckians.
Implications for Practice: Like many chronic physical illnesses, mental illness can be
treated with lifestyle modifications, patient education, psychotherapy, and medications. Granting
psychiatric nurse practitioners additional visits annually can improve care and outcomes for
mentally ill patients in Kentucky.
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Psychiatric APRNs: Removing Payment Barriers in Kentucky

In today’s political environment, healthcare policy has taken the forefront in national
debates and even led to the governmental shutdown in October 2013. The introduction of the
healthcare reform law supports the need for change in our current healthcare systems. In 2003,
In his book, Agenda, Alternatives, and Public Policies, John Kingdon (2003) indicated that
successful policy change requires clear identification of a problem and three streams for change.
In this case, one stream that creates an impetus for change is the observation that
millions of American citizens are underinsured or uninsured, resulting in a well-publicized
healthcare crisis. The second stream requires the involvement of experts willing to support the
need for a proposed change. Mental health professionals at state and federal level support
changes that allow for equitable coverage for mental health and substance abuse services
(Institute of Medicine [IOM], 2011; (Kentucky Cabinet for Health and Family Services, 2013;
"Preventing substance abuse," 2012). The third stream for change relates to the political input,
and whether the proposed policy change will have any support (Kingdon, 2003). The healthcare
reform law has provisions to provide equitable coverage for mental health and substance abuse.
More specifically in Kentucky, the Medicaid Task Force has allowed testimony for expansion of
nurse practitioner services within the state.
Mental illness is a significant problem in the United States. Data from the Department of
Health and Human Services estimate that more than 6% of adults have experienced mental
illness in the last year, and estimates for children are 1 in 10 (SAMHSA, 2011). Kentucky
reports higher than national average numbers for children with attention deficit disorders, adults
with serious mental illness, and suicide rates in high schools ("Preventing substance abuse,"
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2012).Considering this information, the need for an adequately staffed mental health workforce
is significant. Due to the increasing focus on health care, the Commonwealth of Kentucky
commissioned a Healthcare Workforce Capacity committee to investigate the current mental
health treatment demands in the state. The Health Care Workforce Capacity report, also known
as the Deloitte Report, evaluated primary and mental health services in the state. In 2013, the
Deloitte report indicated there are 431 Psychiatrists and 56 Child and Adolescent Psychiatrists
currently in practice in KY (Deloitte, 2013).

In 2007, the Kentucky Institute of Medicine stated

that Kentucky will experience a mental health provider shortage of 48.6% by 2020. At the time
of the study, there were 59 Child and adolescent psychiatrists and 383 psychiatrists in
Kentucky(Kentucky Institute of Medicine, 2007). There is little difference in the number of
practicing psychiatrists in the state during the five year difference between the Kentucky IOM
report and the Deloitte report.
The number of psychiatric (behavioral health) advanced practice nurses (APRN) in the
state is not available via the Kentucky Board of Nursing database. A review of the Kentucky
Coalition of Nurse Practitioners and Nurse Midwives membership roster suggests that there are
fewer than 100 psychiatric APRNs currently in practice in the state. In Kentucky, a psychiatric
APRN can be either a Clinical Nurse Specialist or a psychiatric mental health nurse practitioner
(PMH-NP). The PMH-NP can specialize in the treatment of children/adolescents or families.
PMH NPs are individuals with specialized training and board certification in some aspects of
psychiatry/mental health and are among the only providers who are able to bill for psychiatric
services (Bjorklund, 2003). There have been a variety of reasons that psychiatric APRNs have
been unable to provide those services in Kentucky. These have historically included
reimbursement, prescriptive authority, admitting privileges, and bureaucracy (Dunn, 1997;
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Howard & Greiner, 1997). These barriers are present regardless of the work setting (Heale,
2012).
Background
Kentucky is known as one of the unhealthiest states in the U.S. (Kentucky Coalition of
Nurse Practitioner and Nurse Midwives [KCNPNM], 2010, 2011). One relevant health
indicator measures the number of mentally unhealthy days experienced each month by its
residents. Mentally unhealthy days are currently defined as those that do not allow an individual
to attend to work or activities of daily living. In 2012, Kentucky ranked 48th in the nation for the
prevalence of these mental health days (Kentucky Cabinet for Health and Family Services,
2013). These poor outcomes have been attributed to difficulties in accessing care because of
insurance or provider availability. In 2013, the Deloitte report estimated that it would take 1683
full-time equivalents (FTEs) to meet the current mental health needs in Kentucky. This number
includes both prescribing professionals (psychiatrists, psychiatric APRNs, physician’s assistants)
and non-prescribing professionals (social workers, psychotherapists, and certified alcohol and
drug counselors).
PMH NPs are trained to provide psychotherapy, medication management, advanced
assessments, and psychotherapy (Baradell, 1994; Gournay, 2000; Lovell et al., 2003).
Psychiatric APRNs have the opportunity to meet a unique mental health need as they are able to
provide both medication management visits and psychotherapy. However, Kentucky
Administrative Regulation 1: 104 limits reimbursement of the psychiatric nurse practitioner to
four therapy visits in a 12 month period. This means that although psychiatric APRNs are
reimbursed for the evaluation and management of a patient, they cannot bill for more than four
therapy visits per year. This paper will address the reasons for removal of the limitations on
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psychiatric APRNs’ reimbursement for psychotherapy services. The current regulations do not
provide parity for mental health, are not cost effective, and limit access to providers with a
history of providing quality care.
Parity
In 1996, President Bill Clinton enacted the Mental Health Parity Act, which incorporated
provisions to current insurance plans to enhance and provide mental health coverage that is
equitable to coverage for treatment of medical illnesses. Although this act did not make
provisions for mental health coverage, it was the beginning of a series of acts that would increase
coverage for mental health diagnosis and treatment from employers (www.nami.org).
Kentucky’s version of the parity law appears in Kentucky Regulatory Statue 304.17-318. The
parity regulation states the following:
Any offer to sell a policy or contract of general health insurance to be issued,
Delivered, issued for delivery, amended or renewed in this state after January
1, 1987, shall include an offer of coverage for the inpatient and outpatient
Treatment of mental illness, at least to the same extent and degree as coverage
Provided by the policy or contract for the treatment of physical illnesses
(www.lrc.ky.gov).
Nationally, an additional parity act was created in 2008, but that act does not apply to federally
funded plans, such as the Medicare and Medicaid systems (CMS, 2013). Therefore, the many
individuals who receive Medicare and Medicaid benefits for mental illness and associated
disabilities are not receiving parity in their healthcare (McAllister, 2005).
Quality
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The quality of APRN services has been documented in numerous studies comparing the
quality of physicians to APRNs. Those studies were used in the 2011 report from the Institute of
Medicine, providing documentation that despite the difference in educational preparation, there
is no noticeable difference in the provision for primary care services (Institute of Medicine
[IOM], 2011). The comparison between psychiatric APRNs and psychiatrists has not been
studied as extensively. There is some evidence to support the use of psychiatric APRNs in
medication management and psychotherapy services. A direct comparison of psychiatric and
APRN practices in the treatment of depression indicates that there was no change in medication
adherence (Jacobs, 2005). The same study indicates that psychiatric APRNs spent more time
with the patients while Psychiatrists wrote more prescriptions for anxiolytic agents (Jacobs,
2005). Optimal psychotherapy outcomes rely on both medication management and adequate
time devoted to patient education and prevention. This study supports the role of psychiatric
APRNs as quality providers.
Although patients need increased access to prescribing professionals, such as psychiatric
APRNs, they also require psychotherapy at times to assist with resolution of symptoms. The
effectiveness of treatment provided by PMH NPs has been studied in patient populations with
obsessive compulsive disorder. In a study by Reasor and Farrell (2005), Psychiatric Clinical
Nurse Specialists were noted to have both the appropriate level of training and the ability to
effectively treat psychological conditions. Studies using early intervention as a treatment in
early psychosis have indicated that it is within the scope of Psychiatric APRN practice to
implement those measures (Moore & Proctor, 2011). Early identification in APRN screening
has also been shown to improve outcomes in the Postpartum Depression population. Using
research on best practices, psychiatric APRNs are able to screen and intervene more effectively

22

in mental illnesses and provide evidence based interventions (Neiman, Carter, Van Sell, &
Kindred, 2010). The study only evaluated the psychiatric APRNs' use of evidence based
protocols for management of illness.
Psychiatric APRNs are regarded as providing high quality care in multiple settings
(Cornwell & Chivernton, 1997). For example, psychiatric APRNs are being used to improve
mental health outcomes in emergency rooms (Wand & White, 2007) and school based clinics
(Grossman et al., 2007). They have been known to use identification symptom relief, patient
self-reports, patient determined goals, attaining treatment plan goals, and behavioral changes as
methods to gauge positive and negative patient outcomes (Barrell, Merwin, & Poster, 1997).
These data are critically important when assessing patient outcomes, such as patient satisfaction
and improvement in symptoms and functioning. They can also be considered methods to
decrease patient healthcare costs.
Cost
Currently, Medicare is the standard of reimbursement and is considered the central value
at 100%. Insurance reimbursements are typically 110-120% of the Medicare rate. Kentucky
Medicaid reimburses physicians at 75% of the Medicare reimbursement rate and APRNs at 75%
of the physician’s rate or 54.75% of the Medicare rate. The cost effectiveness of PMH NPs can
be illustrated by an evaluation of reimbursement for a moderately complex new patient visit
(CPT Code 99203), follow-up visit (CPT 99214), and the lowest psychotherapy add-on codes
(CPT 90833; www.cms.gov).
Table 1
Reimbursement Rates for a Moderately Complex Patient
CPT Code

Private Insurance

Medicare
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Medicaid Physician

Medicaid APRN

Reimbursement

Reimbursement

(Psychiatrist)

(73% of the

(110-120%)

(100%)

(75%)

Physician Medicaid
Rate)

99203 (New)

93.41-101.90

84.92

63.69

46.49

99214 (Follow-up)

92.79-101.22

84.35

63.26

46.17

90833 (therapy)

37.68-41.1

34.25

25.68

18.75

At the current reimbursement rates Psychiatric APRNs are being reimbursed at just 54% of the
Medicare rate for providing patient care (www.lrc.ky.gov). Essentially, it is more cost effective
for the state to allow nurse practitioners to see patients.
In an analysis of state level spending from 1997-2005, the Substance Abuse and Mental
Health Services Administration (SAMHSA) found that Kentucky spent $423 per person on
mental health and addiction services (SAMHSA, 2013); further analysis indicated that the
majority of Kentucky’s spending was spent on hospitalizations ($140 per person) and on retail
prescription drugs ($138 per person). An estimate from a Rand Report in 2009 indicates that the
state of Massachusetts could save $4.2-8.4 billion per by expanding the scope for nurse
practitioners and allowing them to practice independently, without any physician oversight
(Eibner, Hussey, Ridgely, & McGlynn, 2009). Although mental health cost effectiveness has not
been studied, APNs have been shown to be effective in cost savings for both heart failure and
pneumonia (Dahle, Smith, Ingersoll, & Wilson, 1998; Gross, Aho, Ashtyani, & Levine, 2004).
Healthcare cost saving is important to every individual and nurse practitioners have been cost
effective in other areas of disease management. Patients should have the opportunity to choose a
provider that is able to meet their needs without having undue restrictions.
Changing 907 KAR 1:104 Section 3 (6)
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From 1997-2005, Kentucky was noted to have a suicide rate higher than the national
average, had a higher rate of fatalities in alcohol related accidents (http://www.samhsa.gov/data),
and was scored at an “F” in 2009 from the National Alliance of Mental Illness: Grading the
States (www.nami.org). Among the reasons for that rating were the decreased funding,
Medicaid spending cuts, and accessibility to mental healthcare. Currently, 80% of counties in
Kentucky have a gap in the number of mental health professionals with 10% of counties needing
25 mental health professionals to meet the current demand for services (Deloitte, 2013). With
budget deficits looming, Kentucky has significantly reduced spending on mental health
(www.nami.org). As a result, Kentucky has seen a large number of mentally unhealthy days
resulting in lost time and disability (Kentucky Cabinet for Health and Family Services, 2013).
Current regulations do not allow for Kentuckians on the Medicaid system to have access
to equitable mental health coverage. In addition, the state does not have enough psychiatrists to
meet the need and these numbers have not increased since 2007 (Deloitte, 2013; Kentucky
Institute of Medicine, 2007). In previous years, the KCNPNM has advocated for the removal of
the barriers for psychiatric APRNs. They are not going to significantly increase the number of
Medicaid dollars spent nor are they competing with psychiatrists for patients. The justification
for the current regulation has always been the potential cost for the state. Psychiatric APRNs
have the potential to help bridge the gap to patients who would otherwise seek treatment in
emergency room settings (Delaney, Hanrahan, & Merwin, 2007; Weber, 2008). Psychiatric
care in an outpatient setting has a lower cost than care sought in an emergency room.
The current regulation also prevents patients from seeking mental healthcare in settings
where a Psychiatric APRN is the sole provider. In community mental health settings, psychiatric
APRNs are able to bypass the regulation by having the psychiatrist see the patient as well and
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then bill for incident to services. This again creates additional cost because the patient is billed
for the physician visit, which is reimbursed at a higher rate. It is unnecessary because psychiatric
APRNs have been shown to be safe and effective (Greenberg, Myer, Sernyak, & Rosenheck,
2006), to use evidence based practice (Crigger & Holcomb, 2008), and to provide cost effective
options for care (KCNPNM, 2010, 2011). Changing the limits on the number of psychotherapy
visits for Kentucky Medicaid recipients would potentially improve the mental health coverage in
the state.
Mental health and substance abuse are currently issues that are important to Kentucky
("Preventing substance abuse," 2012). Assessment and treatment of addiction has often been
referred to mental health professionals for management. With the shortage of psychiatrists in
Kentucky, PMH-NPs are even more important. They can provide additional resources for
assessment and treatment.
Kingdon’s Streams Model
Using Kingdon’s Streams Theory of Policy change, Kentucky is in a unique position to
change the outcomes for thousands of Medicaid recipients who require mental health or
addictions treatment. The Medicaid Commissioner and Medicaid task forces are asking for
suggestions for changes within the system. This is indicative of a positive potential for change in
the political stream. As a provider, it will be important to attend and provide background
information to the Commissioner to support the need for increased access to care. It will also be
important to use the substance abuse and addiction treatment perspective to encourage access.
Second, there is a clearly identified problem on a state and national level. Kentucky law is
currently focused on minimizing substance abuse and addictions. PMH-NPs are an integral part
or maintenance and treatment for patients and provide primary care providers with additional
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referral sources when addictions are detected. The Cabinet for Health and Family services
commissioned the Deloitte report to evaluate the current levels of service within the state. They
study noted that there are significant deficits in access to mental healthcare within the state
(2013). Experts agree and have testified and the Medicaid task force meeting, that mental health
services need to be improved. The information on parity, cost, and quality were presented to the
task force, to encourage the removal of limitations on PMH-NPs.

27

References
Baradell, J. (1994). Cost effectiveness and quality of care provided by clinical nurse specialists.
Journal of Psychosocial Nursing and Mental Health Services, 32(3), 21-24.
Barrell, L. M., Merwin, E. I., & Poster, E. C. (1997, August). Patient outcomes used by advanced
practice psychiatric nurses to evaluate effectiveness of practice. Archives of Psychiatric
Nursing, XI(4), 184-197.
Bjorklund, P. (2003, April). The certified psychiatric nurse practitioner: Advanced practice
psychiatric nursing reclaimed. Archives of Psychiatric Nursing , XVII(2), 77-87.
Cornwell, C., & Chiverton, P. (1997, April). The psychiatric advanced practice with prescriptive
authority: Role development, practice issues, and outcomes measurement. Archives of
Psychiatric Nursing, XI(2), 57-65.
Crigger, N., & Holcomb, L. (2008, February). Improving nurse practitioner practice through
rational prescribing. The Journal for Nurse Practitioners, 120-125.
Dahle, L. K., Smith, J. S., Ingersoll, G. L., & Wilson, J. R. (1998). Brief Reports: impact of a
nurse practitioner on the cost of managing in-patients with heart failure. Excerpta
Medica, 686-688.
Delaney, K. R., Hanrahan, N. P., & Merwin, E. L. (2007, April). Using data to increase the
national presence of psychiatric mental health nursing. Archives of Psychiatric Nursing,
21(2), 112-115.
Deloitte. (2013). The Commonwealth of Kentucky: Health care workforce capacity report.
Retrieved from
http://www.kcnpnm.org/link.asp?e=smpete1@email.uky.edu&job=936531&ymlink=150

28

8485&finalurl=http%3A%2F%2Fhealthbenefitexchange%2Eky%2Egov%2FPages%2Fn
ews%2Easpx%3FwnID%3D7
Dunn, L. (1997). A literature review of advanced clinical nursing practice in the United States of
America. Journal of Advanced Nursing, 25, 814-819.
Eibner, C. E., Hussey, P. S., Ridgely, M. S., & McGlynn, E. A. (2009). Controlling health care
spending in Massachusetts: An analysis of options. Rand Corporation.
Esperat, M. C., & Debisette, A. T. (2012). Nurse-managed health canters: Safety-net care
through advanced nursing practice. Journal of the American Academy of Nurse
Practitioners, 24, 24-31.
Gournay, K. (2000). British nurse in behavior psychotherapy: A 25 year follow-up. Journal of
Advanced Nursing, 32(2), 343-351.
Greenberg, G. A., Myer, J., Sernyak, M., & Rosenheck, R. A. (2006). Access of behavioral
health patients to prescribing professionals. General Hospital Psychiatry, 28, 249-254.
Gross, P., Aho, L., Ashtyani, H., & Levine, J. (2004). Extending the nurse practitioner
concurrent intervention model to community acquired pneumonia and chronic obstructive
pulmonary disease. Joint Commission Journal on Quality and Safety, 30(7), 377-386.
Grossman, J., Laken, M., Stevens, J., Hughes-Joyner, F., Sholar, M., & Gormley, C. (2007,
November). Use of psychiatric nurse practitioner students to provide services in rural
school-based health clinics. Journal of the Child and Adolescent Psychiatric Nursing,
20(4), 234-242.
Heale, R. (2012). Overcoming barriers to practice: A nurse practitioner-led model. Journal of
the American Academy of Nurse Practitioners, 00, 1-6.

29

Howard, P. B., & Greiner, D. (1997, August). Constraints to advanced psychiatric-mental health
nursing practice. Archives of Psychiatric Nursing, XI(4), 198-209.
Institute of Medicine. (2011). The future of nursing: Leading change, advancing health.
Retrieved from http://www.iom.edu/Reports/2010/The-Future-of-Nursing-LeadingChange-Advancing-Health.aspx
Jacobs, J. T. (2005, December). Treatment of depressive disorders in split versus integrated
therapy and comparisons of prescriptive practices of Psychiatrists and Advanced Practice
registered Nurses . Archives of Psychiatric Nursing, 19(6), 256-263.
Kentucky Cabinet for Health and Family Services. (2013). Analysis of the affordable care acts:
Medicaid expansion in Kentucky. Retrieved from
http://governor.ky.gov/healthierky/Documents/MedicaidExpansionWhitePaper.pdf
Kentucky Coalition of Nurse Practitioner and Nurse Midwives. (2010, 2011). Nurse practitioners
and nurse midwives provide quality, cost effective care but barriers to their practice
decrease patient access to care. Retrieved from http://www.kcnpnm.org/members/
Kentucky Institute of Medicine. (2007). Comprehensive Statewide Physician Workforce Study.
Retrieved from kyiom.org/pdf/KMAWorkforceReport9-24-07.pdf
Kingdon, J. W. (2003). Agendas, alternatives, and public policies (2nd ed.). United States:
Addison-Wesley educational Publishers, Inc.
Lovell, K., Cox, D., Garvey, R., Raines, D., Richards, D., & Conroy, P. (2003). Agoraphobia:
Nurse therapist facilitated self-help manual. Journal of Advanced Nursing, 43(6), 2003.
McAllister, M. (2005, May). A health policy paradox: The mind-body disconnect in primary
mental healthcare policy. Part I. Journal of the American Academy of Nurse
Practitioners, 17(5), 163-167.

30

Moore, M., & Proctor, N. (2011). Review: exploring the role of mental health nurse -practitioner
in the treatment of early psychosis. Journal of Clinical Nursing, 20, 2702-2711.
Neiman, S., Carter, S., Van Sell, S., & Kindred, C. (2010). Best practice guidelines for the nurse
practitioner regarding screening, prevention, and management of postpartum depression.
Critical Care Nursing, 33(3), 212-218.
O’Connor, A. B. (2011). Nurse practitioners’ inability to prescribe buprenorphine: Limitations
of the Drug Addiction Treatment Act of 2000. Journal of the America Academy of Nurse
Practitioners, 23, 542-545.
Preventing substance abuse in Kentucky and promoting mental health in Kentucky. (2012).
Retrieved from http://mhmr.ky.gov/mhsas/sa.asp
Reasor, J. E., & Farrell, S. P. (2005, April). The effectiveness of advanced registered nurses as
psychotherapists. Archives of Psychiatric Nursing, 19(2), 81-92.
Santos, J. C., & Amaral, A. S. (2011, October). Effectiveness of psychiatric mental health
nurses: can we save the core of the profession in an economically constrained world?
Archives of Psychiatric Nursing, 25(5), 329-338.
Wand, T., & White, K. (2007). Exploring the scope of the emergency department mental health
nurse practitioner role. Australian College of Mental Health Nurses Inc., 16, 403-412.
Weber, S. (2008). Reimbursement in mental health practice. Journal of the American Academy
of Nurse Practitioners, 20, 443-444.

31

Manuscript 3
Nurse Practitioners and Urine Drug Testing: What do they know?

32

Abstract
Objective: To determine the proficiency in urine drug testing interpretation among nurse
practitioners who order the tests to monitor adherence in their patients on scheduled medications.
Methods: A 28-question instrument, consisting of four questions on participant
demographics, two question on urine drug testing orders, one question on continuing education,
nine questions on urine drug testing interpretation, five questions on response to interpretation,
and seven Likert-scale questions about personal beliefs related to urine drug testing
interpretation. A RedCaps survey was sent out to the 1500 members of the Kentucky Coalition of
Nurse Practitioners and Nurse Midwives. Reminders were sent once per week.
Results: The instrument was completed by 111 advanced practice nurses in the
KCNPNM membership, who subscribe to the organization’s list-serve.
Conclusions: Advanced Practice Registered Nurses who order urine drug testing to
monitor patients on scheduled medications are not consistent in their interpretation and
knowledge of those tests. This study indicates the need for additional education related to urine
drug testing. It is important for APRNs to work closely with laboratory professionals when
interpreting those results.
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Nurse Practitioner and Urine Drug Testing: What do they know?
Introduction
Prescription drug abuse has become an epidemic problem in many states, including
Kentucky. In 2012, Kentucky sought to decrease the number of deaths in the state related to
overdoses of prescription medications. As a result, urine drug screening was mandated by the
Kentucky Board of Medical Licensure and recommended by the Kentucky Board of Nursing to
assess and monitor for appropriate use of prescription medications (http://odcp.ky.gov). These
requirements were implemented as a portion of House Bill 1: The Pill Mill Bill. Originally
intended to address medications for the treatment of pain, each professional board adapted the
law to include many of the drugs of abuse for Kentucky. Since the implementation of House Bill
1, the Office of Drug Control Policy reports that hydrocodone and oxycodone containing
products have decreased 11.8% each, oxymorphone (Opana) decreased 45.5%, and Xanax
14.5%.
Many strategies for monitoring patient medication compliance exist, but urine drug
testing remains the gold standard for compliance. Urine drug testing has the ability to enhance
the prescribing practices of controlled substance prescribers (Gourlay, Heit, & Caplan, 2012). A
variety of methods and screening sensitivity is available and not all of those are appropriate in all
practice sites. Each provider should review their practice type and choose the method of urine
testing that allow them to best monitor those prescribed medications (Hammett-Staber, Pesce, &
Cannon, 2002; Perrone, De Roos, Jayaraman, & Hollander, 2001).
Knowledge and comfort levels related to urine drug screening and interpretation have
been studied in family physicians and internal medicine resident (Reisfield, Webb, Bertholf,
Sloan, & Wilson, 2011). Those studies indicate that internal medicine residents and family
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physicians have a knowledge gap related to urine drug screening. Interpretation of drug
screening and accurate use of those screens can be problematic (Pesce, West, City, & Strickland,
2012). It appears that there are no similar studies in nurse practitioners.
Methods
This descriptive, correlational study was conducted to measure NP knowledge about
urine drug testing and examine the relationship between participants' reported confidence in drug
screen interpretation and the accuracy with which they interpreted findings from drug screens. A
convenience sample of 111 NPs participated in the study. Participants were recruited from the
Kentucky Coalition of Nurse Practitioners and Nurse Midwives (KCNPNM). All KCNPNM
members were eligible to participate, and members were not excluded on the basis of practice
type, location, or retirement status.
An on-line survey was used to collect data. The survey was sent via a list-serve to all
active and subscribing members of KCNPNM, for a total of 1500 eligible participants. A cover
letter was also sent with the survey, which explained the purpose of the study, data collection
methods, and use of the RedCaps survey. The Survey was open to members Oct. 2-30.
Participant recruitment emails were sent to members on October 9, 16, and 23, 2013.
Participation was voluntary and participants were given the opportunity to opt out of the
study at any time. The study was approved by the University of Kentucky Medical Institutional
Review Board and the Executive Director of KCNPNM. Procedures to ensure participant
confidentiality and anonymity were used throughout the study. Participant identity was not
linked to any of the links on the survey.
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Drug Knowledge Assessment Survey.
A 28- item survey was developed specifically for this study to measure NP knowledge of
urine drug interpretation, due to lack of currently available tools. The survey items were
developed using current urine drug screen testing standards. Input was offered from clinical
laboratory experts, including clinical toxicologists. Five of the included interpretation questions
were previously used to study physician knowledge levels by Reisfield et. al (2007). Permission
was obtained to include those questions. Four questions obtained demographic information
related to gender, age group, APRN credentials, and years of practice. Nine questions addressed
specific interpretative knowledge of APRNs on urine drug testing. One question was included to
determine if the APRNs ordered urine drug testing and another asked about continuing education
on urine drug testing. Eleven questions asked the provider questions about general urine drug
testing practices, particularly related to frequency of use and general office management of urine
drug testing. The last portion of the survey asks the APRNs to rate their agreement to statements
regarding urine drug testing and interpretation. Those questions were scored on a Likert scale.
RedCaps administrators harvested the data and only the raw data were sent to the
principal investigator. The data were analyzed using SPSS.
Data Analysis
Frequencies were calculated for each variable. Chi-Square tests were applied to evaluate
reported confidence in urine drug testing and interpretive knowledge. Data was analyzed from a
5-response likert scale, as well as grouping the responses based on agreement, neutral, and
disagreement of confidence levels. The p values, odds ratios, and confidence intervals for
observed associations are reported. A p value of ≥ 0.05 was used to identify statistical
significance.
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Results
The questionnaire (Appendix), was completed by 111 advanced practice nurses. The
participants were mostly female (n=108), nurse practitioners (n=105), and 77% (n=75) had been
in practice more than 5 years. Demographic information is included in table 1. Sixty-five
percent of the participants reported ordering urine drug testing in chronic opioid patients. They
also reported using a variety of urine drug testing methods with in-office testing having the
greatest reported frequency. Only 65% of the participants had attended a continuing education
program on urine drug testing within the last 5 years.
Table 1: Demographic Information
Q1: Gender
Frequency

Percent

Male

8

7.27

Female

102

97.73
Q2: Age Group

Frequency

Percent

18-25

2

1.92

26-34

12

11.54

35-44

22

21.15

45-54

34

32.69

55-64

31

29.81

65 or older

3

2.88
Q3: APN Credentials

Frequency

Percent

Student

3

2.7

APRN-NP

105

94.59

APRN-NM

2

1.8

Retired

1

0.9
Q4: Years in Practice

Frequency

Percent

0-5

36

32.43

6-10

22

19.82

11-15

25

22.52

16-20

15

13.51

37

21-25

5

4.5

>25

8

7.21

Q5: Ordering Testing for Chronic Opioid Therapy patients
Frequency

Percentage

No

37

34.91

Yes

69

65.09

When participants were asked to rate their confidence in interpretation of urine drug
testing results, only 32% of participants agreed/strongly agreed that they were able to interpret.
Eighty-six percent (n=94) of participants agreed/strongly agreed with urine drug testing. Cost of
urine drug testing and cost of laboratory send outs were considered neutrally by participants.
The majority of participants (n=98) agreed/strongly agreed that urine drug testing results would
influence management decisions if patients were identified as taking non-prescription
medications. The majority also agreed/strongly agreed that urine drug specimens should be
screened for adulterants (n=81). Few of the participants (n=27) felt they were confident in
explaining immunoassay/qualitative versus lab/quantitative results.
Table 2 Rating Scales for Urine Drug Testing
Q 22 a: Confidence in interpretation of urine drug screens
Frequency
Percent
Strongly Disagree
15
13.89
Disagree
38
35.19
Neither
20
18.52
Agree
33
30.56
Strongly Agree
2
1.85
Frequency Missing = 3
Q 22 b: No Need for UDT, there are other ways to know what patients take
Frequency
Percent
Strongly Disagree
63
57.8
Disagree
31
28.44
Neither
13
11.93
Agree
1
0.92
Strongly Agree
1
0.92
Frequency Missing = 2
Q 22 C: Consider cost each time for UDT consideration
Frequency
Percentage
Strongly Disagree
13
12.04
Disagree
26
24.07

38

Neither
Agree
Strongly Agree

Strongly Disagree
Disagree
Neither
Agree
Strongly Agree
Q 22 E:
Strongly Disagree
Disagree
Neither
Agree
Strongly Agree

Strongly Disagree
Disagree
Neither
Agree
Strongly Agree

Strongly Disagree
Disagree
Neither
Agree
Strongly Agree

33
30.56
31
28.70
5
4.63
Frequency Missing = 3
Q 22 D: Consider Cost Each time sent to Lab
Frequency
Percentage
9
8.33
24
22.22
27
25
39
36.11
9
8.33
Frequency Missing = 3
UDT Results Change how you manage patients taking non-rx medications
Frequency
Percentage
2
1.83
2
1.83
7
6.42
49
44.95
49
44.95
Frequency Missing = 2
Q 22 F: Important to Test Samples for Adulteration
Frequency
Percentage
1
0.94
1
0.94
23
21.70
48
45.28
33
31.13
Frequency Missing = 5
Q 22 G: Confident Explaining results
Frequency
Percentage
19
17.59
45
41.67
17
15.74
22
20.37
5
4.63
Frequency Missing = 3

The APRN responses to the interpretation question are displayed in table 3. Overall, the
APRN rating of confidence in urine drug testing correlated with increased scores on the
interpretation component. When groups into 3 categories (agree, neutral, and disagree), those
APRNs who rated themselves as confident were more likely to answer the interpretation
questions correctly.
Table 3: Interpretation Scores
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Q 8: Tylenol #3
Frequency
Percentage
Correct
47
42.73
Incorrect
63
57.27
Frequency Missing = 1
Q 14: MS Contin
Frequency
Percentage
Correct
22
20.18
Incorrect
87
79.82
Frequency Missing = 2
Q 15: Reasons for Negative Screen
Frequency
Percentage
Correct
60
54.55
Incorrect
50
45.45
Frequency Missing = 1
Q 16: Chronic Hydromorphone
Frequency
Percentage
Correct
103
94.50
Incorrect
6
5.5
Frequency Missing = 2
Q 17: Valium
Frequency
Percentage
Correct
60
55.56
Incorrect
48
44.44
Frequency Missing = 3
Q 18: Methadone and No other Scripts
Frequency
Percentage
Correct
34
30.63
Incorrect
77
69.37
Frequency Missing = 0
Q 19: Buprenorphine ( 6 panel + buprenorphine)
Frequency
Percentage
Correct
51
46.79
Incorrect
58
53.21
Frequency Missing = 2
Q20: False Positive Benzo POC
Frequency
Percentage
Correct
26
23.42
Incorrect
85
76.58
Frequency Missing = 0
Q 21: False Positive PCP
Frequency
Percentage
Correct
13
11.71
Incorrect
98
88.29
Frequency Missing = 0

Correct answers were assigned 1 point, and the maximum score is 9 points. The
distribution of scores are displayed in graph 1. One APRN did not answer any of the
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interpretation questions correctly and none of the participants were able to answer all of the
questions correctly. The mean number of questions answered correctly was 3.74, median 4.0,
Mode 3.0, standard deviation 1.55, variance 2.42, and range 8.0.

Graph 1

The APRN participants were asked to rate their confidence by a Likert scale agreement
with the statement “I feel confident in my ability to interpret the results of urine drug tests.” Of
the 108 responses to that question 53 participants disagreed with the statement, 20 were neutral
and 35 agreed with the statement. Those responses were compared with the number correct
interpretation responses to determine if confidence can be correlated with accuracy in urine drug
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screen interpretation. The Chi-square value was 3.9291, with two degrees of freedom, Pr>ChiSquare was 0.1402.

There is no statistical significance based upon confidence level.

Only 35 percent of the participants were able to answer more than 4 questions correctly.
The majority of participants provided incorrect answers on items related to Tylenol #3,
methadone, and buprenorphine. Table 4 illustrates the average number of questions answered
correctly based upon the APRN confidence ratings.
Table 4: Mean, Median, Std Dev based on Confidence
Confidence Level in Interpreting UDT results/Number of Correct Interpretation Answers
Strongly Disagree (n=15)
Mean
Median
Std Dev
Min
Max
Score
3.6
3
1.4040757
1
5
Disagree (n = 38)
Score
3.7631579
3.5
1.3839663
1
7
Neither Agree or Disagree (n=20)
Score
3.3
3
1.3416408
1
6
Agree (n=33)
Score
4.0606061
4
1.7842960
1
8
Strongly Agree (n=2)
Score
5
5
1.4142136
4
6

A comparison was also made using responses to the ordering of drug screens. Of the 111
participants, sixty-nine indicated that they order urine drug tests on patients with chronic opioid
therapy. The Chi-square was 1.5022m with 1 degree of freedom, and Pr > Chi-square was
0.2203. Again, there was no significant difference based upon confidence level.
Table 5: Ordering of Drug Screening Differences
Q5 Response

N

Mean

Std Dev

Std Err

Min

Max

No

37

3.4865

1.6094

0.2646

0

7

Yes

69

3.9130

1.4925

0.1797

1

8

-0.4266

1.5340

0.3126

Diff(1-2)
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An additional finding was that when APRNs were faced with unexpected urine drug
testing results (of chronic opioid patients) ninety-two percent would initiate a conversation with
the patient and seventy-six percent would review the treatment agreement. Only seven percent
would change the dose of the opioid, three percent would change to a different opioid, and thirtythree percent would change the management to a non-opioid. Only twenty-six percent of the
participants would increase the frequency of patient visits, thirty-eight percent would increase
the frequency of urine drug testing, and thirty-two percent of the providers would engage
additional providers (psychiatrists, psychologists, etc). Thirty-six percent of the participants
would discharge a patient of unexpected results and eleven percent would notify law
enforcement.
Discussion
Despite the indication in the literature that urine drug testing can be a valid and viable
tool for managing patient drug status, there is a lack of literature to support prescribing provider
knowledge and understanding of the tool. Physicians, APNs, and PAs prescribe medications that
have the potential for abuse but may have different perspectives about the patient’s potential to
abuse them (Hagemeier, Gray, & Pack, 2013). Monitoring medications and interpretation of
urine drug testing adds information to the clinical presentation of the patient and can be used
provide adequate management of many conditions (Moeller et al., 2008). The studies related to
physicians all indicate that there is a difference between what the physician believes they know,
and what they actually understand about urine drug testing and interpretation (Reisfield, Webb,
Bertholf, Sloan, & Wilson, 2007; Starrels et al., 2012). Physician assistant and nurse
practitioners are gaining the opportunity to prescribe and their practices are expanding (Morgan,
De Oliveira, & Short, 2011). If they are prescribing in the same patterns as physicians it is
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reasonable to expect similar confidence levels and misunderstanding about their knowledge
related to urine drug screening (Cipher, Hooker, & Guerra, 2006).
Findings from the study suggest that NP knowledge related to urine drug screening is
overall low. Results of the current study are consistent with the literature and research conducted
with the physician population. It indicates a poor interpretative knowledge level among the
APRN participants who are ordering urine drug testing in patients on scheduled medications.
Their knowledge level was not correlated with their confidence in interpretation indicating a
similar outcome to the studies in physicians. There were no significant associations between
confidence rating of ability and actual ability. In addition, no significant relationships were
found between use of drug screening and correct interpretation among APRNs who drug
screening.
Perhaps the most concerning responses are those related to unexpected urine drug testing
results. Fewer than half of the participants in study would make changes when faced with
unexpected results. Those changes that the participants were most likely to make included
increasing the frequency of urine drug testing and discharging the patient. Increasing the
frequency of testing is a positive approach to management of the results, whereas a patient
discharge can result in very negative outcomes.
Findings suggest that there is no significant relationship between participants' reported
confidence in drug screen interpretation and the accuracy with which they interpreted urine drug
screens. There is also no significant difference in ordering of urine drug testing and accuracy in
interpretation. This finding has implications for NP education and practice. Nurse practitioner
scope and practice has increased and part of that increase has included policy changes in
prescriptive authority (KCNPNM, 2010, 2011). Nurse practitioner prescribing has increased as a
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result. They have been considered safe and effective prescribers, but must continuously review
prescribing guidelines to maintain competence. Substance abuse and addictions have been
considered a psychiatric issue but all providers play a role in effective screening and
management of addictions (Borack, 2002). Urine drug testing education should occur for all
APRNs who prescribe.
APRNs have several resources available for urine drug testing education. In 2008, the
Mayo Clinic published a guide for clinicians for urine drug testing (Moeller et al., 2008). The
manual explains different methods of testing and the benefits and limitations of each. Manuals
and screening tools are available for ordering from the SAMHSA website and provide useful
quick references for urine drug testing and substances of abuse
(http://www.samhsa.gov/data/NSDUH/2k11State/NSDUHsaeTOC2011.htm). Those resources
can be ordered or downloaded for free.
There are limitations to this study. An unvalidated instrument was used to measure the
APRN knowledge levels. Some of the questions were repeated from a prior physician study, but
none had been tested for validity and reliability. The additional questions were included due to
research suggesting that, with the exception of opioid prescribing, general knowledge related to
scheduled medications and urine drug testing is poor outside of opioid prescribing. The
additional questions were added due to concerns related to benzodiazepine abuse and false
positive results. The instrument was reviewed by a clinical toxicologist and adjusted based on
those responses. However, psychometric testing has not been conducted on this survey.
The study results are unable to be generalized to the general APRN population due to the
use of a convenience sample. It is also possible that the sampling method resulted in an unusual
population of individuals interested in urine drug testing and that skewed the responses.
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Conclusion
This study supports that idea that APRNs are poorly informed on the interpretation of
urine drug tests. Thirty-eight percent of the participants reported that they have attended
continuing education on urine drug testing within the last 5 years. This is inconsistent with the
idea that forty-nine percent of the participants felt they were not confident in interpreting the
results of a urine drug test. They are also not able to or are not making changes in their clinical
practices when faced with unexpected urine drug testing results. APRNs need to have more
knowledge about urine drug testing interpretation for clinical practice purpose and to assist them
in making informed treatment decisions for patients. As the focus on prescription drug abuse
increases providers must be more knowledgeable about screening and management.
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Capstone Report Conclusion

Addictions and substance abuse treatment is at the forefront of Kentucky concerns.
Treatment and management of those addictions has become a priority for our legislators (House
Bill 1, 2012). With the implementation of the house bill, all providers, must screen and monitor
patients for substance abuse and addictions. The Kentucky Board of Medical Licensure
mandated urine drug testing in those patients prescribed scheduled medications, and the
Kentucky Board of Nursing recommended urine drug testing for similar issues. In the literature
review, it was noted that physicians generally could not accurately interpret those results, and
APRN knowledge had never been studied. This capstone project investigates that knowledge
and found that APRNs have difficulty interpreting urine drug tests as well.
Historically psychiatric/mental health providers have been integral in addictions
assessments but in Kentucky, regulations limit PMHNPs from working within their full scope.
Psychiatrists are in short supply for the state and they cannot possibly meet the needs of the
patients to provide adequate care. If Kentucky wants to provide enough access to substance
abuse treatment and assessment, PMHNPs need to be allowed to see patients with fewer
restrictions.
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Appendix A
The following 5 questions are for demographic purposes:
1. Identify your Gender
a. Female
b. Male

2. Identify your age group
a. 18-25
b. 26-34
c. 35-44
d. 44-54
e. 55-64
f.

64 +

3. Identify your APRN credentials
a. Student
b. APRN-NP
c. APRN-CNS
d. APRN-NM
e. APRN-CRNA
f.

Retired

4. Number of Years in Practice as an APRN
a. 0-5
b. 6-10
c. 11-15
d. 16-20
e. 21-25
f.

>25

5. Do you currently order urine drug testing for patients on chronic opioid therapy?
a. Yes
b. No
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The following 13 questions are related to your drug testing practices:

6. What method(s) of urine drug testing do you utilize? (Select all that apply)
a. In-Office Immunoassay (cup or dipstick) testing
b. In-Office Immunoassay (desktop analyzer) testing
c. In-Office Immunoassay (cup or dipstick) testing PLUS laboratory (GC-MS or LCMS/MS) testing
d. In-Office Immunoassay (desktop analyzer) testing PLUS laboratory (GC-MS or LCMS/MS) testing

e. Laboratory (GC-MS or LC-MS/MS) testing ONLY
f.

Other

7. In the last 5 years, have you attended any continuing education on urine drug testing or
interpretation?
a. Yes
b. No
8. In a patient prescribed Tylenol #3 (codeine and acetaminophen), which of the following could be
positive on UDT results based on parent and metabolite detection? (Check One)
a. Codeine
b. Oxycodone
c. Morphine
d. All of the Above
e. A and C only

9. What types of monitoring do you use besides urine drug testing? (check all that apply)
a. None
b. Pill counts
c. PDMP (online state drug prescription monitoring program)
d. Observation (i.e., body language, aberrant behaviors)\
e. Treatment agreements
10. What do you believe are the reasons to utilize drug monitoring? (check all that apply)
a. As a baseline measure of what a new patient may or may not have recently taken
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b. Determine / document presence of a prescribed medication or medication(s)
c. Determine / document abstinence from illicit drugs and non-prescribed
medications
d. Identify early relapses for those with a history of addiction
e. Protect practice/self
f. Help to determine need to continue or discontinue certain treatments
g. UDT helps patients remain abstinent because they know they will be tested
regularly
h. UDT helps patients anticipate that there will be consequences of nonprescribed
drug use
11. How often do you use UDT to help manage your patients’ prescribed chronic opioids?
(check all that apply)
a. Never
b. Baseline testing only for new patients
c. Baseline testing for new patients plus random testing
d. Every office visit
e. Random testing only for all patients
f. When I have evidence to warrant testing in a patient with aberrant behavior (e.g.,
lost prescriptions, early refills, etc.)
12. What factors influence your decision to use/order a UDT? (check all that apply)
a. Patient history
b. Psychiatric history
c. Abuse history
d. Family history
e. Length of time with SUD
f. Aberrant behaviors or red flags
g. Legal involvement
h. Court mandate
i. Pregnancy
j. Patient presentation
k. To help manage medication regimen
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13. In response to a UDT unexpected result (UDT positive for a non-prescribed medication
or illicit substance OR negative for a prescribed medication), I typically manage the
patient in the following ways: (check all that apply)
a. Initiated a conversation with the patient to determine why
b. Review the treatment agreement
c. Changed the dose of opioid
d. Changed the opioid to a different opioid
e. Change the opioid to a non-opioid
f. Scheduled the patient to be seen more frequently
g. Performed UDT more frequently
h. Engaged additional providers (e.g., psychiatrist, psychologist)
i. Discharge the patient
j. Report to law enforcement
14. What types of monitoring do you use besides urine drug testing? (check all that apply)
a. None
b. Pill counts
c. PDMP (online state drug prescription monitoring program)
d. Observation (i.e., body language, aberrant behaviors)\
e. Treatment agreements
15. What do you believe are the reasons to utilize drug monitoring? (check all that apply)
a. As a baseline measure of what a new patient may or may not have recently taken
b. Determine / document presence of a prescribed medication or medication(s)
c. Determine / document abstinence from illicit drugs and non-prescribed
medications
d. Identify early relapses for those with a history of addiction
e. Protect practice/self
f. Help to determine need to continue or discontinue certain treatments
g. UDT helps patients remain abstinent because they know they will be tested
regularly
h. UDT helps patients anticipate that there will be consequences of non-prescribed
drug use
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16. How often do you use UDT to help manage your patients’ prescribed chronic opioids?
(check all that apply)
a. Never
b. Baseline testing only for new patients
c. Baseline testing for new patients plus random testing
d. Every office visit
e. Random testing only for all patients
f. When I have evidence to warrant testing in a patient with aberrant behavior (e.g.,
lost prescriptions, early refills, etc.)
17. What factors influence your decision to use/order a UDT? (check all that apply)
a. Patient history
b. Psychiatric history
c. Abuse history
d. Family history
e. Length of time with SUD
f. Aberrant behaviors or red flags
g. Legal involvement
h. Court mandate
i. Pregnancy
j. Patient presentation
k. To help manage medication regimen
18. In response to a UDT unexpected result (UDT positive for a non-prescribed medication
or illicit substance OR negative for a prescribed medication), I typically manage the
patient in the following ways: (check all that apply)
a. Initiated a conversation with the patient to determine why
b. Review the treatment agreement
c. Changed the dose of opioid
d. Changed the opioid to a different opioid
e. Change the opioid to a non-opioid
f. Scheduled the patient to be seen more frequently
g. Performed UDT more frequently
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h. Engaged additional providers (e.g., psychiatrist, psychologist)
i. Discharge the patient
j. Report to law enforcement
k.
The following 8 questions are related to your urine drug testing knowledge:
19. In a patient prescribed MS Contin (extended-release morphine), which of the following could be
positive on UDT based on parent and metabolite detection? (check one)
a. Morphine
b. Codeine
c. Hydromorphone
d. All of the above
e. A and C only
20. The following are possible reasons for a negative urine opiate screen on in-office point-of-care
(POC) immunoassay (cup or dipstick) in a patient prescribed long-acting opioid therapy: (Check
One)
a. Patient ran out early and has not used any in a few days
b. Patient is a “rapid metabolizer” of the enzyme which metabolizes that specific opioid
c. Test does not detect that particular opioid
d. A, B, and C
e. A and C only
21. A patient on chronic hydromorphone therapy tests negative for opioids on an in-office POC
immunoassay (cup or dipstick) urine drug test, but claims to be using the medication around the
clock as prescribed. The most appropriate next step would be to : (Check One)
a. Subject this urine to a more specific method of test, such as GC-MS or LC-MS/MS
b. Continue the medication as prescribed and re-administer am in-office POC immunoassay
test at the next visit
c. Taper and discontinue the opioid therapy
d. Refer the patient to a detoxification/rehabilitation center
e. Notify law enforcement
22. In a patient prescribed diazepam (Valium®), which of the following could be positive on UDT
based on parent and metabolite detection? (Check One)
a. Nordiazepam
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b. Temazepam
c. Oxazepam
d. All of the above
e. A and C only

23. Mr. Smith is a 50 year old man with a 10 year history of difficult to treat chronic back
pain with a neuropathic component. His current treatment plan includes prescribed
methadone and no other controlled substances or opioids. He presents for his clinic
appointment today and his clinician orders an in-office urine drug screen. Which of the
following would you expect to be positive on an in-office POC immunoassay UDT (6
panel)? (Check One)
a. Opiates
b. Cocaine
c. Amphetamine
d. Methamphetamine
e. THC
f. Benzodiazepines
g. None of the above
24. Michael is a 27 yo man with a history of prescription opioid addiction. He is currently
prescribed buprenorphine. As a condition of his on-going treatment he is subject to
random urine drug testing. The results of the in-office POC immunoassay UDT (6 panel
+ buprenorphine cup) are as follows:

Opiates – positive
Cocaine – negative
Amphetamine – negative
Methamphetamine – negative
THC – negative
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Benzodiazepines – negative
Buprenorphine – positive

These results are satisfactory to document he is adherent to the treatment plan
(i.e., taking the buprenorphine and not using to taking any additional medications
or illicit drugs)
a. ____ True
b. ____ False

25. Which of the following medications or compounds can cause a false positive result for
benzodiazepines on an immunoassay POC (cup or dipstick) urine drug test? (Check One)
a. sertraline (Zoloft®)
b. Vick’s® nasal inhaler
c. diphenhydramine (Benadryl®)
d. all of the above
e. A and C only
26. Which of the following medications or compounds can cause a false positive result for
Phencyclidine, PCP (i.e., angel dust) on an immunoassay POC (cup or dipstick) urine
drug test? (Check One)
a. venlafaxine (Effexor®)
b. dextromethorphan
c. diphenhydramine (Benadryl®)
d. ibuprofen
e. All of the above

The last questions related to your feelings about urine drug testing:
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Please read the statements below and

Strongly Disagree Neither

choose the response that most closely

disagree

matches your beliefs.

agree

Agree

Strongly
agree

nor
disagree

I feel confident in my ability to interpret the
results of urine drug tests.
I don’t need to do UDT because I have
other ways to know what my patients are
taking.
I consider cost each time I decide whether
to do UDT.
I consider cost each time I decide whether
to send a specimen for laboratory testing.
I would change how I manage a patient if I
find they are taking prescription
medications that I (or a prescriber I work
closely with) have not prescribed.
It is important to test urine specimens for
adulteration.
I am very confident explaining the
differences between
“immunoassay/qualitative” and
“laboratory/quantitative” urine drug testing.
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